Inside Precision Medicine

  • Home
  • Inside Precision Medicine

Inside Precision Medicine Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Inside Precision Medicine, Media/News Company, 140 Huguenot Street, .

Exclusive news, features, and analysis on the research, tools, regulations, and applications driving the future of precision medicine with the ultimate goal of transforming patient care and outcomes. Driven by a rapid and exponentially growing market – one that is expected to be valued at more than $126 billion by 2025 – and our commitment to covering the full breadth of the revolutionary field of precision medicine, Clinical OMICs is now Inside Precision Medicine! Inside Precision Medicine is the only global media brand covering the full spectrum of precision medicine, taking a wide lens approach while bringing into sharp focus the many complex and interconnected issues that constitute the field. From our core areas of Translational Research, Molecular Diagnostics, Informatics, and Patient Care, to our expanded coverage of Disease Indications and Payer/Regulatory issues, our best-in-class content informs, educates, and enlightens our diverse audience of leading decision-makers.

H. pylori May Contribute to Colorectal Cancer Risk WorldwideA global analysis links H. pylori exposure to increased colo...
12/09/2026

H. pylori May Contribute to Colorectal Cancer Risk Worldwide

A global analysis links H. pylori exposure to increased colorectal cancer risk and explores whether eradication could offer an additional cancer prevention strategy. The new findings pointing to possible roles for the gut microbiome, immune signaling, and epithelial changes.

UC San Diego, The University of Hong Kong, Erasmus MC, Brown University

A global analysis links H. pylori exposure to increased colorectal cancer risk and explores whether eradication could offer an additional cancer prevention strategy.

Guardant360 CDx Test Approved for Early, 'Serial' Use in Breast CancerThe Guardant360 CDx liquid biopsy test has been U....
12/09/2026

Guardant360 CDx Test Approved for Early, 'Serial' Use in Breast Cancer

The Guardant360 CDx liquid biopsy test has been U.S. Food and Drug Administration approved as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in certain advanced patients. This is the first test approved to manage treatment before testing tumor size. “For decades, doctors have largely waited for a scan to show that a tumor has grown before changing treatment,” Helmy Eltoukhy, Guardant Health chairman and co-CEO told IPM.

AstraZeneca

The Guardant360 CDx liquid biopsy test has been FDA approved as a companion diagnostic for AstraZeneca’s ETCAMAH (camizestrant) in certain advanced patients. This is the first test approved to manage treatment before testing tumor size.

Translational Microbiomics Offsets Ecological DisruptionsA combination of three different antibodies and antiretroviral ...
12/09/2026

Translational Microbiomics Offsets Ecological Disruptions

A combination of three different antibodies and antiretroviral therapy seems to permanently clear HIV from infant macaques with a simian version of the virus. “The really exciting part is that it could go to clinical trials immediately to eliminate HIV infection in newborns,” said co-lead author Jonah Sacha, PhD, professor and senior researcher at Oregon Health & Science University (OHSU), in a press statement. “The next step after that is to test if this can work in newly exposed adults.”


A combination of three antibodies and antiretroviral therapy seems to clear HIV from infant macaques with a simian version of the virus.

Riaan’s Therapeutic Odyssey – Chapter 2: The ResearchersIn creating a gene therapy for Cockayne syndrome, University of ...
11/09/2026

Riaan’s Therapeutic Odyssey – Chapter 2: The Researchers

In creating a gene therapy for Cockayne syndrome, University of Massachusetts researchers overcame financing, regulation, and manufacturing challenges to help future patients.

Check back next week for the third chapter of this five-part series, the pediatric neurologist who led the charge to build the infrastructure for experimental gene therapy administration discusses first-in-human risk and CNS delivery and what hospitals must become if bespoke genetic medicines proliferate.

Riaan Research Initiative, Charles River Labs, Andelyn Biosciences,

A mother worked with University of Massachusetts researchers to develop a gene therapy for her son's untreatable neurodevelopmental disease.

Childhood Chemotherapy Leaves Lasting DNA Damage in Healthy TissuesCertain chemotherapy drugs can age children’s healthy...
11/09/2026

Childhood Chemotherapy Leaves Lasting DNA Damage in Healthy Tissues

Certain chemotherapy drugs can age children’s healthy cells, with some children showing levels of genetic damage comparable to those found in adult tissues. To understand these changes, University of Gothenburg's Anna Wenger, PhD’s team used a genomic sequencing method developed at the Wellcome Sanger Institute, which sequences both strands of DNA independently and compares results to achieve high resolution.

The Francis Crick Institute, University of Cambridge,

Certain chemotherapy drugs can age children’s healthy cells to levels comparable to those found in adult tissues.

Prostate Cancer Genomic Analysis Links Mutational Footprints to Clinical OutcomesEight genetic footprints explain 85% of...
10/09/2026

Prostate Cancer Genomic Analysis Links Mutational Footprints to Clinical Outcomes

Eight genetic footprints explain 85% of mutational processes in prostate cancer genomes and could improve risk stratification and treatment selection.

“We have effectively created a map of the biological processes that drive prostate cancer,” said Joachim Weischenfeldt, PhD, professor at the Biotech Research & Innovation Centre at the Københavns Universitet - University of Copenhagen and Rigshospitalet, and co-lead author of the study.


Eight genetic footprints explain 85% of mutational processes in prostate cancer genomes and could improve risk stratification and treatment selection.

🎙️ Roche Diagnostics Is Ramping Up—Should Illumina, Inc. Be Worried?To bring cutting-edge diagnostic platforms to clinic...
10/09/2026

🎙️ Roche Diagnostics Is Ramping Up—Should Illumina, Inc. Be Worried?

To bring cutting-edge diagnostic platforms to clinical use, Roche introduced the AXELIOS sequencing-by-expansion (SBX) sequencer. In IPM's latest episode of Behind the Breakthroughs, Jonathan Grinstein, PhD, spoke with Palani Kumaresan, PhD, Global Head of Roche Diagnostic Solutions to get more insight on Roche Diagnostics' return to next-generation sequencing.


To bring cutting-edge diagnostic platforms to clinical use, Roche introduced the AXELIOS sequencing-by-expansion (SBX) sequencer.

HLA Gene Variant Linked to Severe Reaction from Anti-Seizure MedicationAdding HLA-A*32:01 to pharmacogenomic testing cou...
09/09/2026

HLA Gene Variant Linked to Severe Reaction from Anti-Seizure Medication

Adding HLA-A*32:01 to pharmacogenomic testing could improve risk stratification for lamotrigine-induced DRESS before patients begin treatment. Matthew Krantz, MD, from Vanderbilt University Medical Center, and co-authors explain that drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, potentially fatal drug hypersensitivity reaction characterized by extensive skin eruption, fever, lymphadenopathy, and internal organ involvement. It carries a mortality rate of three percent to 10%.

Vanderbilt Health

Adding HLA-A*32:01 to pharmacogenomic testing could improve risk stratification for lamotrigine-induced DRESS before patients begin treatment.

Common European Genetic Variants Linked with Parkinson’s ProgressionThe study results could help identify a large geneti...
09/09/2026

Common European Genetic Variants Linked with Parkinson’s Progression

The study results could help identify a large genetic subgroup with a poorer prognosis, who would benefit from being included in clinical studies of potentially disease-modifying treatments.

The research highlights the promise of progression genetics, commented Christine Klein, MD, from the Universität zu Lübeck in an accompanying editorial.


Genetic variants found in more than half of people with European ancestry are associated with faster motor decline in Parkinson's disease.

Peptide Microdroplets Rewire the PD-1/PD-L1 Checkpoint in Resistant Colorectal CancerResearchers at Nanyang Technologica...
08/09/2026

Peptide Microdroplets Rewire the PD-1/PD-L1 Checkpoint in Resistant Colorectal Cancer

Researchers at Nanyang Technological University, Singapore, developed peptide microdroplets that deliver siRNA to T cells and tumor cells, suppressing colorectal tumor growth in mice.


Researchers developed peptide microdroplets that deliver siRNA to T cells and tumor cells, suppressing colorectal tumor growth in mice.

Address

140 Huguenot Street

10801

Website

Alerts

Be the first to know and let us send you an email when Inside Precision Medicine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

  • Want your business to be the top-listed Media Company?

Share